Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
1-15 of 4029 results
Xenon’s acne drug XEN801 fails in phase 2 trial
By PBR Staff Writer
A phase 2 trial of Xenon Pharmaceuticals’ acne drug XEN801 has failed to meet its efficacy endpoints in patients having moderate to severe acne.
Contract Research & Services > Clinical Trials > News
Akashi gets FDA nod to restart clinical development of DMD drug HT-100
Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).
Contract Research & Services > Clinical Trials > News
Novartis’ serelaxin fails to meet primary endpoint in heart failure study
By PBR Staff Writer
Novartis' RLX030 (serelaxin) has failed to meet its primary endpoint in a phase III acute heart failure (AHF) study.
Contract Research & Services > Clinical Trials > News
Lilly’s abemaciclib meets primary endpoint in phase 3 breast cancer trial
By PBR Staff Writer
A phase 3 study of Lilly’s breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
Nektar’s NKTR-181 shown to reduce chronic pain in phase 3 trial
Nektar Therapeutics’ NKTR-181 has met primary and secondary endpoints in phase 3 SUMMIT-07 study in chronic pain.
Contract Research & Services > Clinical Trials > News
Novartis’ heart failure drug Entresto improves glycemic control in Phase III study
Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril.
Contract Research & Services > Clinical Trials > News
Amgen's Repatha lowers heart attack, stroke risk in phase 3 study
By PBR Staff Writer
A phase 3 study has demonstrated that Amgen’s cholesterol drug Repatha reduces low-density lipoprotein cholesterol (LDL-C) levels and risk of cardiovascular events.
Contract Research & Services > Clinical Trials > News
Catalyst Pharmaceuticals’ neuromuscular drug succeeds in seven-patient trial
By PBR Staff Writer
Catalyst Pharmaceuticals said its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a debilitating neuromuscular disease, met the main goals of a study.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Lynparza shows significant survival benefit in ovarian cancer study
By PBR Staff Writer
A phase 3 clinical trial evaluating AstraZeneca's PARP inhibitor Lynparza (olaparib) as maintenance therapy in ovarian cancer demonstrated a pronounced extension in survival compared to placebo.
Contract Research & Services > Clinical Trials > News
Indivior plans to file NDA for schizophrenia drug in Q4 2017
Indivior has unveield positive top-line 12-Month phase 3 results confirming long-term safety profile of RBP-7000 in patients with schizophrenia.
Contract Research & Services > Clinical Trials > News
Synairgen eyes lung fibrosis trial after positive data from LOXL2 inhibitor program
By PBR Staff Writer
Synairgen is on track to begin the initial clinical trial of a new lung fibrosis treatment later this year after pre-clinical work showed more evidence of improved breathing.
Contract Research & Services > Clinical Trials > News
BerGenBio signs deal with Merck to test lung and breast cancer combo
BerGenBio has signed a collaborative agreement with Merck focused the clinical study of BGB324 with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Contract Research & Services > Clinical Trials > News
Mereo BioPharma committee recommends continuation of BGS-649 study
Mereo BioPharma said that an independent data monitoring committee has recommended to continue all three different dose arms of the Phase 2b BGS-649 study after a prospectively defined interim analysis of safety and efficacy.
Contract Research & Services > Clinical Trials > News
TG Therapeutics’ cancer drug meets primary end point in phase 3 trial
By PBR Staff Writer
TG Therapeutics’ cancer drug, TG-1101 (ublituximab), in combination with AbbVie’s Imbruvica (ibrutinib), has met its primary end point in a phase 3 study in chronic lymphocytic leukemia (CLL) patients.
Contract Research & Services > Clinical Trials > News
FDA asks Scynexis to hold initiation of new clinical studies using IV formulation of SCY-078
Scynexis has been asked by the US Food and Drug Administration (FDA) to put a hold on the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until it finishes a review of all available pre-clinical and clinical data of the IV formulation of SCY-078.
Contract Research & Services > Clinical Trials > News
1-15 of 4029 results